# EDGAR Filing Document

**Accession Number:** 0001829247
**File Stem:** 0000000000-25-009844
**Filing Date:** 2025-9
**Character Count:** 3391
**Document Hash:** b9dc7395ea8d4583b7bfeca64d65a63b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009844.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0000000000-25-009844

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250910

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BullFrog AI Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001829247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844786155
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-41600

**BUSINESS ADDRESS:**
- **STREET 1:** 325 ELLINGTON BLVD.
- **STREET 2:** UNIT 317
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878
- **BUSINESS PHONE:** 3013672055

**MAIL ADDRESS:**
- **STREET 1:** 325 ELLINGTON BLVD.
- **STREET 2:** UNIT 317
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-010367

## Text-Extract

```

                                                            September 10, 2025

Josh Blacher
Chief Financial Officer
BullFrog AI Holdings, Inc.
325 Ellington Blvd. , Unit 317
Gaithersburg , MD 20878

       Re: BullFrog AI Holdings, Inc.
           Form 10-K for Fiscal Year Ended December 31, 2024
           File No. 001-41600
Dear Josh Blacher:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for Fiscal Year Ended December 31, 2024
Financial Statements, page F-1

1.     We note you have entered into agreements with the Lieber Institute for
Brain
       Development, Eleison Pharmaceuticals, Inc., and Sygnature Discovery
Limited.
       Please address the following:
           Revise your disclosure, in future filings, as applicable, to provide
a more
           comprehensive discussion of their terms, including but not limited
to, the rights
           and obligations of each party, consideration, amounts paid and
received to date,
           milestone amounts, royalty amounts, and termination provisions.
           File the related agreements, or tell us where you have previously
filed them.
           Alternatively, tell us why they are not required to be filed
pursuant to Item
           601(b)(10) of Regulation S-K.

        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.
 September 10, 2025
Page 2

       Please contact Tracie Mariner at 202-551-3744 or Jenn Do at 202-551-3743
with any
questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._